Core Viewpoint - American Rebel Holdings, Inc. has filed an appeal with Nasdaq to contest a delisting determination, allowing its common stock and warrants to continue trading on Nasdaq during the appeal process [1][2][9]. Appeal and Reversal of Prior Decision - The appeal was submitted on February 11, 2026, before the deadline, which automatically stays any suspension or delisting actions [2][9]. - The decision to appeal marks a significant reversal from the company's earlier stance of not appealing and preparing to transition to OTC Markets [4][10]. - The appeal was driven by stockholder feedback, emphasizing the importance of maintaining the Nasdaq listing for liquidity and visibility [2][6]. Context of Nasdaq Delisting Notice - Nasdaq's delisting determination on February 4, 2026, was due to the company's failure to maintain a minimum bid price of $1.00 for 30 consecutive business days, compounded by multiple reverse stock splits [8][10]. - The company had conducted four reverse stock splits since October 2024, with a cumulative ratio of 1-for-90,000, which disqualified it from the standard compliance grace period [8][10]. Hearing Process and Contingency Plans - The company is preparing to present a compliance plan to an independent Nasdaq Hearings Panel, with a hearing expected in the coming weeks [2][9]. - While pursuing the appeal, the company is also preparing for a potential transition to OTC Markets if necessary, as part of its contingency plans [8][10]. CEO Perspective - The CEO emphasized the company's commitment to stockholders and the importance of the appeal in preserving stockholder value, particularly for small investors [5][6]. - The appeal is seen as a strategic move to maintain stability and visibility for the company and its investors while executing its business strategy [7][10].

CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to delist its common stock. Palatin Technologies® is a registered trademark of Palatin Technologies, Inc. SOURCE Palatin Technologies, Inc. Company working aggressively to r ...